Hypoactivity

Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2022 Financial Results and Provides a Business Update

Retrieved on: 
Friday, November 12, 2021
Mental Health, Health, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, Securities Exchange Act of 1934, Compliance, Capsule, Addiction, Method, Hypoactivity, Form 10-K, Clinical trial, THC, Good manufacturing practice, Securities Act of 1933, Medication, SAB, Annual report, Company, Brain, Solution, SEC, Drug Quality and Security Act, Mouse, Weight loss, Nasdaq, Patent, Emergency medicine, CB1, Pharmaceutical industry, ANEB-001, Anebulo Pharmaceuticals, Inc., ANEB-001, ANEBULO PHARMACEUTICALS, INC.

Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance addiction, today announced financial results for the first quarter of its fiscal year ending June 30, 2022 and reported recent business highlights.

Key Points: 
  • Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance addiction, today announced financial results for the first quarter of its fiscal year ending June 30, 2022 and reported recent business highlights.
  • The patent provides protection through 2040 and describes use of the Companys investigational drug ANEB-001 to treat acute cannabinoid overdose.
  • Operating expenses in the first quarter of fiscal 2022 were $1,554,924 compared with $252,346 in the same period in fiscal 2021.
  • Except as required by federal securities law, Anebulo Pharmaceuticals undertakes no obligation to update or revise forward-looking statements to reflect changed conditions.

Anebulo Pharmaceuticals Announces Issuance of U.S. Patent Covering Use of ANEB-001 for the Treatment of Acute Cannabinoid Overdose

Retrieved on: 
Wednesday, October 13, 2021
Biotechnology, Pharmaceutical, General Health, Health, FDA, Mental Health, Clinical Trials, Other Health, Securities Exchange Act of 1934, Method, Solution, Addiction, Nasdaq, Mouse, Trial of the century, Weight loss, Securities Act of 1933, SEC, Brain, CB1, Hypoactivity, Patent, Form 10-K, Annual report, MD, 1836 U.S. Patent Office fire, Medication, Pharmaceutical industry

The issued patent describes the use of the Companys investigational drug ANEB-001 to treat acute cannabinoid overdose and is expected to provide patent protection through 2040.

Key Points: 
  • The issued patent describes the use of the Companys investigational drug ANEB-001 to treat acute cannabinoid overdose and is expected to provide patent protection through 2040.
  • There is a large and growing unmet need to treat acute cannabinoid intoxication, and we believe ANEB-001 has the ability to reverse symptoms safely and rapidly.
  • Anebulo Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance addiction.
  • Its lead product candidate, ANEB-001, is intended to reverse the negative effects of acute cannabinoid intoxication within one hour of administration.

Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides a Business Update

Retrieved on: 
Wednesday, September 22, 2021
Biotechnology, Pharmaceutical, Health, Mental Health, THC, Mouse, CB1, Clinical trial, Securities Act of 1933, Annual report, Weight loss, Compliance, SAB, Addiction, Solution, Drug Quality and Security Act, Patient, Nasdaq, Medication, Good manufacturing practice, Form 10-K, Company, Hypoactivity, Capsule, IPO, Brain, Calendar, Securities Exchange Act of 1934, Emergency medicine, Time, SEC, Pharmaceutical industry, Security (finance), ANEB-001, Anebulo Pharmaceuticals, Inc., ANEB-001, ANEBULO PHARMACEUTICALS, INC.

Business highlights for the fourth quarter of fiscal year 2021 and recent weeks include the following:

Key Points: 
  • Business highlights for the fourth quarter of fiscal year 2021 and recent weeks include the following:
    Completed manufacturing of ANEB-001 capsules for upcoming Phase 2 clinical trial.
  • Operating expenses in the fourth quarter of fiscal 2021 were $2,484,705 compared with $173,351 in the same period in fiscal 2020.
  • Net loss in the fourth quarter of fiscal 2021 was $29,111,739, or $(1.59) per share, compared with a net loss of $174,637, or $(0.01) per share, in the fourth quarter of fiscal 2020.
  • Except as required by federal securities law, Anebulo Pharmaceuticals undertakes no obligation to update or revise forward-looking statements to reflect changed conditions.

Anebulo Pharmaceuticals Announces Completion of Manufacturing of ANEB-001 Capsules for Upcoming Phase 2 Clinical Trial

Retrieved on: 
Monday, September 13, 2021
Biotechnology, Managed Care, Other Health, Health, General Health, Pharmaceutical, Mental Health, Other Science, Research, Science, Clinical Trials, Form, Addiction, Mouse, Medication, Weight loss, Securities Exchange Act of 1934, Trial of the century, Good manufacturing practice, CB1, Drug Quality and Security Act, Nasdaq, Solution, Hypoactivity, Capsule, Brain, Securities Act of 1933, Compliance, SEC, Pharmaceutical industry, ANEB-001, Anebulo Pharmaceuticals, Inc., ANEB-001, ANEBULO PHARMACEUTICALS, INC.

In compliance with all current Good Manufacturing Practice requirements, ANEB-001s active pharmaceutical ingredient was delivered to its contract manufacturer and filled into 10mg and 50mg capsules for finished product.

Key Points: 
  • In compliance with all current Good Manufacturing Practice requirements, ANEB-001s active pharmaceutical ingredient was delivered to its contract manufacturer and filled into 10mg and 50mg capsules for finished product.
  • Completion of manufacturing ANEB-001 capsules is a critical step in advancing the development of our drug candidate for the treatment of acute cannabis intoxication, stated Daniel Schneeberger, M.D., Chief Executive Officer of Anebulo.
  • Anebulo Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance addiction.
  • Except as required by federal securities law, Anebulo Pharmaceuticals undertakes no obligation to update or revise forward-looking statements to reflect changed conditions.

Global Attention Deficit Hyperactivity Disorder Market Insights, Epidemiology and Market Forecast 2016-2018 & 2027

Retrieved on: 
Thursday, January 24, 2019
Psychiatry, Attention deficit hyperactivity disorder, Psychology, Childhood psychiatric disorders, Psychiatric diagnosis, Amphetamine, Educational psychology, Attention deficit, Adult attention deficit hyperactivity disorder, Hypoactivity

The "Attention Deficit Hyperactivity Disorder (ADHD) - Market Insights, Epidemiology and Market Forecast-2027" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Attention Deficit Hyperactivity Disorder (ADHD) - Market Insights, Epidemiology and Market Forecast-2027" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • Attention Deficit Hyperactivity Disorder (ADHD) - Market Insights, Epidemiology and Market Forecast-2027' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Attention Deficit Hyperactivity Disorder (ADHD) in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.
  • The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Attention Deficit Hyperactivity Disorder (ADHD) from 2016 to 2027 segmented by seven major markets.
  • According to this research, the market of Attention Deficit Hyperactivity Disorder (ADHD) in 7MM is expected to change from 2016-2027.